Opendata, web and dolomites

PEVIA SIGNED

PAN EBOLA VACCINE INNOVATIVE APPROACH – Sofia ref.: 116088

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PEVIA project word cloud

Explore the words cloud of the PEVIA project. It provides you a very rough idea of what is the project "PEVIA" about.

outbreaks    dangerous    immunogenicity    east    endemic    zaire    ebola    caused    spurred    disease    did    lasting    strain    risk    1976    outbreak    reached    infection    severe    severity    historic    underscoring    human    hence    pattern    fatality    vaccines    preventive    highest    discovery    combined    humans    safety    isolated    vaccine    spread    rapid    microorganisms    occurred    filoviridae    global    monovalent    strains    mostly    rural    safe    regions    demonstrating    primates    attract    approved    event    antiviral    species    serious    public    family    stomatitis    causing    immune    efficacy    west    hemorrhagic    ebov    larger    clinical    sporadic    shown    vesicular    trials    gained    models    africa    world    central    people    workers    infections    virus    proportions    magnitude    prevention    readily    protective    fevers    confined    induce    candidates    lethal    patients    caring    2014    viruses    protect    animal    threat    took    drugs    treatment    health    healthcare    vector   

Project "PEVIA" data sheet

The following table provides information about the project.

Coordinator
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS 

Organization address
address: 3 AVENUE VICTORIA
city: PARIS
postcode: 75000
website: http://www.aphp.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.pevia-ebola.eu
 Total cost 17˙731˙397 €
 EC max contribution 6˙189˙570 € (35%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-08-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2023-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) coordinator 1˙297˙406.00
2    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 1˙040˙108.00
3    OLIGOVAX FR (PARIS) participant 863˙000.00
4    CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE FR (LILLE) participant 603˙125.00
5    UNIVERSITE D'ABOMEY-CALAVI BJ (ABOMEY CALAVI) participant 566˙312.00
6    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 533˙332.00
7    IFAKARA HEALTH INSTITUTE TRUST TZ (DAR ES SALAAM) participant 502˙000.00
8    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 273˙650.00
9    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 246˙887.00
10    BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN DE (HAMBURG) participant 182˙500.00
11    HEINRICH-PETTE INSTITUT LEIBNIZ INSTITUT FUER EXPERIMENTELLE VIROLOGIE DE (HAMBURG) participant 81˙250.00
12    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 0.00
13    EXCELLGENE SA CH (MONTHEY) participant 0.00
14    VAXEAL RESEARCH FR (EVRY) participant 0.00

Map

 Project objective

Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified.

A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PEVIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PEVIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More